MedTrace Logo

Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC

NCT04459234 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2023-09-11

No results posted yet for this study

Summary

The primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation…) and administration protocol (route, posology, duration, administration sequence, premedication).

The secondary objectives are to evaluate in the context of cancer, the analgesic efficacy, the tolerance profile (biological and clinical toxicities) and the quality of life, including anxiety and depression.

In addition, the described parameters will be evaluated as safety and efficacy predictive factors of the Ketamine in oncology.

Conditions

Interventions

DRUG

Ketamine use in CLCC sites (indication and administration protocol)

Collection of information concerning Ketamine use by French CLCCs pain teams (first prescription): 1. Indications : analgesic treatment of cancer chronic pain, analgesic treatment for a post-cancer treatment chronic pain, help for withdrawal from opioid treatment prescribed for a chronic cancer pain 2. Administration protocol: route, posology, duration, administration sequence, premedication 3. Antalgic efficacy 4. Tolerance profile 5. Quality of life, anxiety and depression evaluations

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Gisèle CHVETZOFF, MD · Centre Leon Berard

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-02
Primary Completion
2023-02-06
Completion
2023-03-09

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04459234 on ClinicalTrials.gov